Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moMEFOXIN (cefoxitin sodium) by Merck & Co. is clinical pharmacology clinical pharmacology following an intravenous dose of 1 gram, serum concentrations were 110 mcg/ml at 5 minutes, declining to less than 1 mcg/ml at 4 hours. Approved for serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below, infection in patients undergoing uncontaminated gastrointestinal surgery, vaginal hysterectomy and 2 more indications. First approved in 1987.
Drug data last refreshed Yesterday
CLINICAL PHARMACOLOGY Clinical Pharmacology Following an intravenous dose of 1 gram, serum concentrations were 110 mcg/mL at 5 minutes, declining to less than 1 mcg/mL at 4 hours. The half-life after an intravenous dose is 41 to 59 minutes. Approximately 85 percent of cefoxitin is excreted…
Worked on MEFOXIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo